NDAC to discuss ipecac
This article was originally published in The Tan Sheet
FDA advisory committee will consider the "safety and efficacy of ipecac syrup indicated for emergency use to cause vomiting in poisoning cases for continued OTC status" during a June 12 meeting. Primary areas of consideration will be: status of the role of ipecac syrup in gastrointestinal decontamination; whether the literature clearly defines the syrup's risk/benefit ratio; the role of ipecac in poison treatment for populations with limited access to emergency medical treatment; whether there is significant abuse of ipecac; and alternative therapies to ipecac syrup, FDA says. NDAC meeting will begin at 8 a.m. at the Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md...
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.